<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1060">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147350</url>
  </required_header>
  <id_info>
    <org_study_id>RP-6306-03</org_study_id>
    <nct_id>NCT05147350</nct_id>
  </id_info>
  <brief_title>Study of RP-6306 With FOLFIRI in Advanced Solid Tumors</brief_title>
  <acronym>MINOTAUR</acronym>
  <official_title>Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination With FOLFIRI for the Treatment of Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repare Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repare Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of RP-6306 with&#xD;
      FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose&#xD;
      (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess&#xD;
      preliminary anti-tumor activity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose Escalation and expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with of treatment-related adverse event data per CTCAE v5.0 criteria and frequency of dose limiting toxicities, to determine safety and tolerability of RP-6306 in combination with FOLFIRI.</measure>
    <time_frame>Up to 90 days after last administration of study intervention</time_frame>
    <description>This data will be used to identify a recommended phase 2 dose (RP2D) and schedule of RP-6306 in combination with FOLFIRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To identify a maximum tolerated dose (MTD) through evaluation of dose-limiting toxicities (DLTs) at or below a frequency of 25%.</measure>
    <time_frame>Up to 90 days after last administration of study intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary efficacy of RP-6306 in combination with FOLFIRI using RECIST v1.1 criteria to determine the overall response rate (ORR) at each tested dose level.</measure>
    <time_frame>Through study completion, up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) from time 0 to 8 hours post dose</measure>
    <time_frame>Through end of study, up to 2 months</time_frame>
    <description>PK parameters of RP-6306, irinotecan, and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) will be observed directly from data</measure>
    <time_frame>Through end of study, up to 2 months</time_frame>
    <description>PK parameters of RP-6306, irinotecan, and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum blood plasma concentration (Cmin) will be observed directly from data</measure>
    <time_frame>Through end of study, up to 2 months</time_frame>
    <description>PK parameters of RP-6306, irinotecan, and SN-38</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time take to reach Cmax (Tmax) will be observed directly from data as time of first occurrence</measure>
    <time_frame>Through end of study, up to 2 months</time_frame>
    <description>PK parameters of RP-6306, irinotecan, and SN-38</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RP-6306 (oral PKMYT1 inhibitor)</intervention_name>
    <description>RP-6306 (Oral) in combination with FOLFIRI (IV)</description>
    <arm_group_label>Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation</arm_group_label>
    <other_name>FOLFIRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female and ≥18 years-of-age at the time of signature of the informed consent&#xD;
&#xD;
          -  Confirmed advanced solid tumors resistant or refractory to standard treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.&#xD;
&#xD;
          -  All patients must have locally advanced or metastatic CRC, GI, or esophageal cancer(s)&#xD;
             and radiographic evidence of progressing disease.&#xD;
&#xD;
          -  Measurable disease as per RECIST v1.1&#xD;
&#xD;
          -  Submission of available tumor tissue or willingness to have a biopsy performed if safe&#xD;
             and feasible&#xD;
&#xD;
          -  Acceptable hematologic and organ function at screening&#xD;
&#xD;
          -  Negative pregnancy test for women of childbearing potential at Screening and prior to&#xD;
             first study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to swallow and retain oral medications.&#xD;
&#xD;
          -  Chemotherapy or small molecule antineoplastic agent given within 21 days or &lt;5 half-&#xD;
             lives, whichever is shorter, prior to first dose of study treatment.&#xD;
&#xD;
          -  History or current condition, therapy, or laboratory abnormality that might confound&#xD;
             the study results, or interfere with the patient's participation for the full duration&#xD;
             of the study treatment.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  Life-threatening illness, medical condition, active uncontrolled infection, or organ&#xD;
             system dysfunction or other reasons which, in the investigator's opinion, could&#xD;
             compromise the participating patient's safety.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to first study treatment dose.&#xD;
&#xD;
          -  Uncontrolled, symptomatic brain metastases.&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  Active, uncontrolled bacterial, fungal, or viral infection, including hepatitis B&#xD;
             virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV), or&#xD;
             acquired immunodeficiency syndrome (AIDS) related illness.&#xD;
&#xD;
          -  Moderate or severe hepatic impairment&#xD;
&#xD;
          -  Cardiac diseases currently or within the last 6 months as defined by New York Heart&#xD;
             Association (NYHA) ≥Class 2&#xD;
&#xD;
          -  Psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol and/or follow-up procedures outlined in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter Manley, MD</last_name>
    <phone>+1 617 999 0547</phone>
    <email>pmanley@reparerx.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

